APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

API Drug Development Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global API Drug Development Service Market Analysis and Forecast 2026-2032

Report ID 17406792023 May 2026244 pages

Choose your research edition.

Industry ResearchAPI Drug Development Service Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal API Drug Development Service Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal API Drug Development Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal API Drug Development Service Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal API Drug Development Service Market Analysis and Forecast 2026-2032244 pages · $4,950 USD

Market perspective

The global API Drug Development Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for API Drug Development Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for API Drug Development Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for API Drug Development Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for API Drug Development Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of API Drug Development Service include Lonza, Patheon, Catalent, Carbogen Amcis, Sterling Pharma Solutions, Cambrex, CordenPharma, Eurofins Scientific and Malvern Panalytical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for API Drug Development Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of API Drug Development Service, also provides the revenue of main regions and countries. Of the upcoming market potential for API Drug Development Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the API Drug Development Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global API Drug Development Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for API Drug Development Service revenue, projected growth trends, production technology, application and end-user industry.

API Drug Development Service Segment by Company

Lonza

Patheon

Catalent

Carbogen Amcis

Sterling Pharma Solutions

Cambrex

CordenPharma

Eurofins Scientific

Malvern Panalytical

Almac

Pfizer

Axplora

Aptuit

Porton

Pharmaron Beijing

Shanghai Haoyuan Chemexpress

Stapharma

API Drug Development Service Segment by Type

Captive Product Development Service

Commercial Product Development Service

API Drug Development Service Segment by Application

Small Biotechs Companies

Large Pharmaceutical Organizations

API Drug Development Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global API Drug Development Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of API Drug Development Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of API Drug Development Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of API Drug Development Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of API Drug Development Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, API Drug Development Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global API Drug Development Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Captive Product Development Service Major Player Table 3. Commercial Product Development Service Major Player Table 4. Global API Drug Development Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Small Biotechs Companies Major Player Table 6. Large Pharmaceutical Organizations Major Player Table 7. API Drug Development Service Industry Trends Table 8. API Drug Development Service Industry Drivers Table 9. API Drug Development Service Industry Opportunities and Challenges Table 10. API Drug Development Service Industry Restraints Table 11. Global API Drug Development Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global API Drug Development Service Market Size by Region (2021-2026) & (US$ Million) Table 13. Global API Drug Development Service Market Share by Region (2021-2026) Table 14. Global API Drug Development Service Market Size by Region (2027-2032) & (US$ Million) Table 15. Global API Drug Development Service Market Share by Region (2027-2032) Table 16. Global API Drug Development Service Revenue by Players (US$ Million) & (2021-2026) Table 17. Global API Drug Development Service Revenue Market Share by Players (2021-2026) Table 18. Global API Drug Development Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global API Drug Development Service Key Players Headquarters & Area Served Table 20. Global API Drug Development Service Players, Product Type & Application Table 21. Global API Drug Development Service Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global API Drug Development Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global API Drug Development Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global API Drug Development Service Revenue by Type (2021-2026) & (US$ Million) Table 26. Global API Drug Development Service Revenue by Type (2027-2032) & (US$ Million) Table 27. Global API Drug Development Service Revenue Market Share by Type (2021-2026) Table 28. Global API Drug Development Service Revenue Market Share by Type (2027-2032) Table 29. Global API Drug Development Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global API Drug Development Service Revenue by Application (2021-2026) & (US$ Million) Table 31. Global API Drug Development Service Revenue by Application (2027-2032) & (US$ Million) Table 32. Global API Drug Development Service Revenue Market Share by Application (2021-2026) Table 33. Global API Drug Development Service Revenue Market Share by Application (2027-2032) Table 34. Lonza Company Information Table 35. Lonza Business Overview Table 36. Lonza API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Lonza API Drug Development Service Product Portfolio Table 38. Lonza Recent Development Table 39. Patheon Company Information Table 40. Patheon Business Overview Table 41. Patheon API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Patheon API Drug Development Service Product Portfolio Table 43. Patheon Recent Development Table 44. Catalent Company Information Table 45. Catalent Business Overview Table 46. Catalent API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Catalent API Drug Development Service Product Portfolio Table 48. Catalent Recent Development Table 49. Carbogen Amcis Company Information Table 50. Carbogen Amcis Business Overview Table 51. Carbogen Amcis API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Carbogen Amcis API Drug Development Service Product Portfolio Table 53. Carbogen Amcis Recent Development Table 54. Sterling Pharma Solutions Company Information Table 55. Sterling Pharma Solutions Business Overview Table 56. Sterling Pharma Solutions API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Sterling Pharma Solutions API Drug Development Service Product Portfolio Table 58. Sterling Pharma Solutions Recent Development Table 59. Cambrex Company Information Table 60. Cambrex Business Overview Table 61. Cambrex API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Cambrex API Drug Development Service Product Portfolio Table 63. Cambrex Recent Development Table 64. CordenPharma Company Information Table 65. CordenPharma Business Overview Table 66. CordenPharma API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. CordenPharma API Drug Development Service Product Portfolio Table 68. CordenPharma Recent Development Table 69. Eurofins Scientific Company Information Table 70. Eurofins Scientific Business Overview Table 71. Eurofins Scientific API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Eurofins Scientific API Drug Development Service Product Portfolio Table 73. Eurofins Scientific Recent Development Table 74. Malvern Panalytical Company Information Table 75. Malvern Panalytical Business Overview Table 76. Malvern Panalytical API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Malvern Panalytical API Drug Development Service Product Portfolio Table 78. Malvern Panalytical Recent Development Table 79. Almac Company Information Table 80. Almac Business Overview Table 81. Almac API Drug Development Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Almac API Drug Development Service Product Portfolio Table 83. Almac Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer API Drug Development Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 87. Pfizer API Drug Development Service Product Portfolio Table 88. Pfizer Recent Development Table 89. Axplora Company Information Table 90. Axplora Business Overview Table 91. Axplora API Drug Development Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Axplora API Drug Development Service Product Portfolio Table 93. Axplora Recent Development Table 94. Aptuit Company Information Table 95. Aptuit Business Overview Table 96. Aptuit API Drug Development Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Aptuit API Drug Development Service Product Portfolio Table 98. Aptuit Recent Development Table 99. Porton Company Information Table 100. Porton Business Overview Table 101. Porton API Drug Development Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Porton API Drug Development Service Product Portfolio Table 103. Porton Recent Development Table 104. Pharmaron Beijing Company Information Table 105. Pharmaron Beijing Business Overview Table 106. Pharmaron Beijing API Drug Development Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Pharmaron Beijing API Drug Development Service Product Portfolio Table 108. Pharmaron Beijing Recent Development Table 109. Shanghai Haoyuan Chemexpress Company Information Table 110. Shanghai Haoyuan Chemexpress Business Overview Table 111. Shanghai Haoyuan Chemexpress API Drug Development Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Shanghai Haoyuan Chemexpress API Drug Development Service Product Portfolio Table 113. Shanghai Haoyuan Chemexpress Recent Development Table 114. Stapharma Company Information Table 115. Stapharma Business Overview Table 116. Stapharma API Drug Development Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Stapharma API Drug Development Service Product Portfolio Table 118. Stapharma Recent Development Table 119. North America API Drug Development Service Revenue by Type (2021-2026) & (US$ Million) Table 120. North America API Drug Development Service Revenue by Type (2027-2032) & (US$ Million) Table 121. North America API Drug Development Service Revenue by Application (2021-2026) & (US$ Million) Table 122. North America API Drug Development Service Revenue by Application (2027-2032) & (US$ Million) Table 123. North America API Drug Development Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. North America API Drug Development Service Revenue by Country (2021-2026) & (US$ Million) Table 125. North America API Drug Development Service Revenue by Country (US$ Million) & (2027-2032) Table 126. Europe API Drug Development Service Revenue by Type (2021-2026) & (US$ Million) Table 127. Europe API Drug Development Service Revenue by Type (2027-2032) & (US$ Million) Table 128. Europe API Drug Development Service Revenue by Application (2021-2026) & (US$ Million) Table 129. Europe API Drug Development Service Revenue by Application (2027-2032) & (US$ Million) Table 130. Europe API Drug Development Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Europe API Drug Development Service Revenue by Country (2021-2026) & (US$ Million) Table 132. Europe API Drug Development Service Revenue by Country (US$ Million) & (2027-2032) Table 133. China API Drug Development Service Revenue by Type (2021-2026) & (US$ Million) Table 134. China API Drug Development Service Revenue by Type (2027-2032) & (US$ Million) Table 135. China API Drug Development Service Revenue by Application (2021-2026) & (US$ Million) Table 136. China API Drug Development Service Revenue by Application (2027-2032) & (US$ Million) Table 137. Asia API Drug Development Service Revenue by Type (2021-2026) & (US$ Million) Table 138. Asia API Drug Development Service Revenue by Type (2027-2032) & (US$ Million) Table 139. Asia API Drug Development Service Revenue by Application (2021-2026) & (US$ Million) Table 140. Asia API Drug Development Service Revenue by Application (2027-2032) & (US$ Million) Table 141. Asia API Drug Development Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 142. Asia API Drug Development Service Revenue by Region (US$ Million) & (2021-2026) Table 143. Asia API Drug Development Service Revenue by Region (US$ Million) & (2027-2032) Table 144. SAMEA API Drug Development Service Revenue by Type (2021-2026) & (US$ Million) Table 145. SAMEA API Drug Development Service Revenue by Type (2027-2032) & (US$ Million) Table 146. SAMEA API Drug Development Service Revenue by Application (2021-2026) & (US$ Million) Table 147. SAMEA API Drug Development Service Revenue by Application (2027-2032) & (US$ Million) Table 148. SAMEA API Drug Development Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. SAMEA API Drug Development Service Revenue by Country (2021-2026) & (US$ Million) Table 150. SAMEA API Drug Development Service Revenue by Country (US$ Million) & (2027-2032) Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. API Drug Development Service Image Figure 2. Global API Drug Development Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global API Drug Development Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. Captive Product Development Service Image Figure 5. Commercial Product Development Service Image Figure 6. Global API Drug Development Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global API Drug Development Service Market Size Share 2021 VS 2025 VS 2032 Figure 8. Small Biotechs Companies Image Figure 9. Large Pharmaceutical Organizations Image Figure 10. Global API Drug Development Service Market Size (US$ Million) & (2021-2032) Figure 11. Global API Drug Development Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global API Drug Development Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global API Drug Development Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global API Drug Development Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global API Drug Development Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global API Drug Development Service Revenue Market Share by Type (2021-2032) Figure 18. Global API Drug Development Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global API Drug Development Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global API Drug Development Service Revenue Market Share by Application (2021-2032) Figure 21. North America API Drug Development Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America API Drug Development Service Revenue Share by Type (2021-2032) Figure 23. North America API Drug Development Service Revenue Share by Application (2021-2032) Figure 24. North America API Drug Development Service Revenue Share by Country (2021-2032) Figure 25. United States API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe API Drug Development Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe API Drug Development Service Revenue Share by Type (2021-2032) Figure 30. Europe API Drug Development Service Revenue Share by Application (2021-2032) Figure 31. Europe API Drug Development Service Revenue Share by Country (2021-2032) Figure 32. Germany API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China API Drug Development Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China API Drug Development Service Revenue Share by Type (2021-2032) Figure 42. China API Drug Development Service Revenue Share by Application (2021-2032) Figure 43. Asia API Drug Development Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia API Drug Development Service Revenue Share by Type (2021-2032) Figure 45. Asia API Drug Development Service Revenue Share by Application (2021-2032) Figure 46. Asia API Drug Development Service Revenue Share by Region (2021-2032) Figure 47. Japan API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA API Drug Development Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA API Drug Development Service Revenue Share by Type (2021-2032) Figure 55. SAMEA API Drug Development Service Revenue Share by Application (2021-2032) Figure 56. SAMEA API Drug Development Service Revenue Share by Country (2021-2032) Figure 57. Brazil API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt API Drug Development Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Captive Product Development Service
  • Commercial Product Development Service
Applications
  • Small Biotechs Companies
  • Large Pharmaceutical Organizations
Companies covered
  • Lonza
  • Patheon
  • Catalent
  • Carbogen Amcis
  • Sterling Pharma Solutions
  • Cambrex
  • CordenPharma
  • Eurofins Scientific
  • Malvern Panalytical
  • Almac
  • Pfizer
  • Axplora
  • Aptuit
  • Porton
  • Pharmaron Beijing
  • Shanghai Haoyuan Chemexpress
  • Stapharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 API Drug Development Service Market by Type
  3. 1.2.1 Global API Drug Development Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Captive Product Development Service
  5. 1.2.3 Commercial Product Development Service
  6. 1.3 API Drug Development Service Market by Application
  7. 1.3.1 Global API Drug Development Service Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Small Biotechs Companies
  9. 1.3.3 Large Pharmaceutical Organizations
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 API Drug Development Service Market Dynamics
  1. 2.1 API Drug Development Service Industry Trends
  2. 2.2 API Drug Development Service Industry Drivers
  3. 2.3 API Drug Development Service Industry Opportunities and Challenges
  4. 2.4 API Drug Development Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global API Drug Development Service Market Perspective (2021-2032)
  2. 3.2 Global API Drug Development Service Growth Trends by Region
  3. 3.2.1 Global API Drug Development Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global API Drug Development Service Market Size by Region (2021-2026)
  5. 3.2.3 Global API Drug Development Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global API Drug Development Service Revenue by Players
  2. 4.1.1 Global API Drug Development Service Revenue by Players (2021-2026)
  3. 4.1.2 Global API Drug Development Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global API Drug Development Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global API Drug Development Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global API Drug Development Service Key Players Headquarters & Area Served
  7. 4.4 Global API Drug Development Service Players, Product Type & Application
  8. 4.5 Global API Drug Development Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global API Drug Development Service Market CR5 and HHI
  11. 4.6.3 2025 API Drug Development Service Tier 1, Tier 2, and Tier 3
5 API Drug Development Service Market Size by Type
  1. 5.1 Global API Drug Development Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global API Drug Development Service Revenue by Type (2021-2032)
  3. 5.3 Global API Drug Development Service Revenue Market Share by Type (2021-2032)
6 API Drug Development Service Market Size by Application
  1. 6.1 Global API Drug Development Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global API Drug Development Service Revenue by Application (2021-2032)
  3. 6.3 Global API Drug Development Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lonza
  2. 7.1.1 Lonza Company Information
  3. 7.1.2 Lonza Business Overview
  4. 7.1.3 Lonza API Drug Development Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lonza API Drug Development Service Product Portfolio
  6. 7.1.5 Lonza Recent Developments
  7. 7.2 Patheon
  8. 7.2.1 Patheon Company Information
  9. 7.2.2 Patheon Business Overview
  10. 7.2.3 Patheon API Drug Development Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Patheon API Drug Development Service Product Portfolio
  12. 7.2.5 Patheon Recent Developments
  13. 7.3 Catalent
  14. 7.3.1 Catalent Company Information
  15. 7.3.2 Catalent Business Overview
  16. 7.3.3 Catalent API Drug Development Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Catalent API Drug Development Service Product Portfolio
  18. 7.3.5 Catalent Recent Developments
  19. 7.4 Carbogen Amcis
  20. 7.4.1 Carbogen Amcis Company Information
  21. 7.4.2 Carbogen Amcis Business Overview
  22. 7.4.3 Carbogen Amcis API Drug Development Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Carbogen Amcis API Drug Development Service Product Portfolio
  24. 7.4.5 Carbogen Amcis Recent Developments
  25. 7.5 Sterling Pharma Solutions
  26. 7.5.1 Sterling Pharma Solutions Company Information
  27. 7.5.2 Sterling Pharma Solutions Business Overview
  28. 7.5.3 Sterling Pharma Solutions API Drug Development Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sterling Pharma Solutions API Drug Development Service Product Portfolio
  30. 7.5.5 Sterling Pharma Solutions Recent Developments
  31. 7.6 Cambrex
  32. 7.6.1 Cambrex Company Information
  33. 7.6.2 Cambrex Business Overview
  34. 7.6.3 Cambrex API Drug Development Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Cambrex API Drug Development Service Product Portfolio
  36. 7.6.5 Cambrex Recent Developments
  37. 7.7 CordenPharma
  38. 7.7.1 CordenPharma Company Information
  39. 7.7.2 CordenPharma Business Overview
  40. 7.7.3 CordenPharma API Drug Development Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 CordenPharma API Drug Development Service Product Portfolio
  42. 7.7.5 CordenPharma Recent Developments
  43. 7.8 Eurofins Scientific
  44. 7.8.1 Eurofins Scientific Company Information
  45. 7.8.2 Eurofins Scientific Business Overview
  46. 7.8.3 Eurofins Scientific API Drug Development Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Eurofins Scientific API Drug Development Service Product Portfolio
  48. 7.8.5 Eurofins Scientific Recent Developments
  49. 7.9 Malvern Panalytical
  50. 7.9.1 Malvern Panalytical Company Information
  51. 7.9.2 Malvern Panalytical Business Overview
  52. 7.9.3 Malvern Panalytical API Drug Development Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Malvern Panalytical API Drug Development Service Product Portfolio
  54. 7.9.5 Malvern Panalytical Recent Developments
  55. 7.10 Almac
  56. 7.10.1 Almac Company Information
  57. 7.10.2 Almac Business Overview
  58. 7.10.3 Almac API Drug Development Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Almac API Drug Development Service Product Portfolio
  60. 7.10.5 Almac Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer API Drug Development Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer API Drug Development Service Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 Axplora
  68. 7.12.1 Axplora Company Information
  69. 7.12.2 Axplora Business Overview
  70. 7.12.3 Axplora API Drug Development Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Axplora API Drug Development Service Product Portfolio
  72. 7.12.5 Axplora Recent Developments
  73. 7.13 Aptuit
  74. 7.13.1 Aptuit Company Information
  75. 7.13.2 Aptuit Business Overview
  76. 7.13.3 Aptuit API Drug Development Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Aptuit API Drug Development Service Product Portfolio
  78. 7.13.5 Aptuit Recent Developments
  79. 7.14 Porton
  80. 7.14.1 Porton Company Information
  81. 7.14.2 Porton Business Overview
  82. 7.14.3 Porton API Drug Development Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Porton API Drug Development Service Product Portfolio
  84. 7.14.5 Porton Recent Developments
  85. 7.15 Pharmaron Beijing
  86. 7.15.1 Pharmaron Beijing Company Information
  87. 7.15.2 Pharmaron Beijing Business Overview
  88. 7.15.3 Pharmaron Beijing API Drug Development Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Pharmaron Beijing API Drug Development Service Product Portfolio
  90. 7.15.5 Pharmaron Beijing Recent Developments
  91. 7.16 Shanghai Haoyuan Chemexpress
  92. 7.16.1 Shanghai Haoyuan Chemexpress Company Information
  93. 7.16.2 Shanghai Haoyuan Chemexpress Business Overview
  94. 7.16.3 Shanghai Haoyuan Chemexpress API Drug Development Service Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Shanghai Haoyuan Chemexpress API Drug Development Service Product Portfolio
  96. 7.16.5 Shanghai Haoyuan Chemexpress Recent Developments
  97. 7.17 Stapharma
  98. 7.17.1 Stapharma Company Information
  99. 7.17.2 Stapharma Business Overview
  100. 7.17.3 Stapharma API Drug Development Service Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Stapharma API Drug Development Service Product Portfolio
  102. 7.17.5 Stapharma Recent Developments
8 North America
  1. 8.1 North America API Drug Development Service Revenue (2021-2032)
  2. 8.2 North America API Drug Development Service Revenue by Type (2021-2032)
  3. 8.2.1 North America API Drug Development Service Revenue by Type (2021-2026)
  4. 8.2.2 North America API Drug Development Service Revenue by Type (2027-2032)
  5. 8.3 North America API Drug Development Service Revenue Share by Type (2021-2032)
  6. 8.4 North America API Drug Development Service Revenue by Application (2021-2032)
  7. 8.4.1 North America API Drug Development Service Revenue by Application (2021-2026)
  8. 8.4.2 North America API Drug Development Service Revenue by Application (2027-2032)
  9. 8.5 North America API Drug Development Service Revenue Share by Application (2021-2032)
  10. 8.6 North America API Drug Development Service Revenue by Country
  11. 8.6.1 North America API Drug Development Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America API Drug Development Service Revenue by Country (2021-2026)
  13. 8.6.3 North America API Drug Development Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe API Drug Development Service Revenue (2021-2032)
  2. 9.2 Europe API Drug Development Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe API Drug Development Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe API Drug Development Service Revenue by Type (2027-2032)
  5. 9.3 Europe API Drug Development Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe API Drug Development Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe API Drug Development Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe API Drug Development Service Revenue by Application (2027-2032)
  9. 9.5 Europe API Drug Development Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe API Drug Development Service Revenue by Country
  11. 9.6.1 Europe API Drug Development Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe API Drug Development Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe API Drug Development Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China API Drug Development Service Revenue (2021-2032)
  2. 10.2 China API Drug Development Service Revenue by Type (2021-2032)
  3. 10.2.1 China API Drug Development Service Revenue by Type (2021-2026)
  4. 10.2.2 China API Drug Development Service Revenue by Type (2027-2032)
  5. 10.3 China API Drug Development Service Revenue Share by Type (2021-2032)
  6. 10.4 China API Drug Development Service Revenue by Application (2021-2032)
  7. 10.4.1 China API Drug Development Service Revenue by Application (2021-2026)
  8. 10.4.2 China API Drug Development Service Revenue by Application (2027-2032)
  9. 10.5 China API Drug Development Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia API Drug Development Service Revenue (2021-2032)
  2. 11.2 Asia API Drug Development Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia API Drug Development Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia API Drug Development Service Revenue by Type (2027-2032)
  5. 11.3 Asia API Drug Development Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia API Drug Development Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia API Drug Development Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia API Drug Development Service Revenue by Application (2027-2032)
  9. 11.5 Asia API Drug Development Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia API Drug Development Service Revenue by Country
  11. 11.6.1 Asia API Drug Development Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia API Drug Development Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia API Drug Development Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA API Drug Development Service Revenue (2021-2032)
  2. 12.2 SAMEA API Drug Development Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA API Drug Development Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA API Drug Development Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA API Drug Development Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA API Drug Development Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA API Drug Development Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA API Drug Development Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA API Drug Development Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA API Drug Development Service Revenue by Country
  11. 12.6.1 SAMEA API Drug Development Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA API Drug Development Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA API Drug Development Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst